This effect was confirmed by a more recent KAMILLA study (NCT01702571), wherein T-DM1 demonstrated CNS-specific benefit in patients with HER2+ BC with BMs [128], supporting the manageable safety profile and use of T-DM1 in advanced BC [129]. Here, ERBB2 is linked to breast cancer.